# Altitude Life Science Ventures

> Altitude Life Science Ventures is a VC fund backing Biotechnology. See 50 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Durango, United States
- Total investments: 50
- Last investment: Oct 2025
- Lead investor: 4%
- Last updated: Aug 2026
- Website: https://www.altitudelsv.com/

Altitude Life Science Ventures is a VC fund in Durango focused on Biotechnology and Health Care. Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses.build portfolio among attractive life science sectors in a manner that balances risk while maximizing potential synergies and ultimatereturns. Our focus is on opportunities in biotechnology, medical devices, and diagnostics, but we are continually responsive to the best areas for investing in order to adapt to changing market conditions.Invest in companies that: * are pursuing substantial and growing market opportunities * possess a unique and proprietary technology, with a clear competitive advantage * are early-stage opportunities * have or will attract strong management * have a strong investment syndicate * offer a defined path to liquidity

## Contacts

5 contacts available for Altitude Life Science Ventures. Shizune tracks 1 team members at Altitude Life Science Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/altitude-life-science-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 30 | 60% |
| Health Care | 14 | 28% |
| Therapeutics | 12 | 24% |
| Medical | 10 | 20% |
| Life Science | 6 | 12% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 16 | 32% |
| Series A | 13 | 26% |
| Series C | 11 | 22% |
| Funding Round | 3 | 6% |
| Series D | 2 | 4% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Steve Johnson | Co-Founder and Partner | 0 | https://shizune.co/investors/profile/steve-johnson-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ansa Biotechnologies | Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $46.4M | Series B | Oct 01, 2025 |  |
| Lila Sciences | Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $200M | Seed | Mar 10, 2025 |  |
| Vilya | Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases. | $21M | Series A | Jun 04, 2024 |  |
| Ring Therapeutics | Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company isexpanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases. | $86.5M | Series C | Mar 09, 2023 |  |
| Escient Pharmaceuticals | Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $120M | Series C | Nov 28, 2022 |  |
| Neumora Therapeutics | Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. | $112M | Series B | Oct 11, 2022 |  |
| Tessera Therapeutics | Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | $300M | Series C | Apr 19, 2022 |  |
| Tessera Therapeutics | Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | $300M | Series C | Apr 19, 2022 |  |
| Ansa Biotechnologies | Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $68M | Series A | Apr 11, 2022 |  |
| Generate Biomedicines | Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. | $370M | Series B | Nov 18, 2021 |  |

10 of 50 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 28 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 13 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 9 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 8 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 6 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Altitude Life Science Ventures invest in?

Altitude Life Science Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 50 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Altitude Life Science Ventures?

Public channels for Altitude Life Science Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Altitude Life Science Ventures?

The team at Altitude Life Science Ventures includes Steve Johnson (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co